APOE4 testing checks whether you carry the ε4 variant of the APOE gene, and the result tells your doctor how likely you are to develop ARIA—a brain-imaging side effect—if you start an anti-amyloid Alzheimer's drug. The higher your ε4 "dose" (one copy or two), the higher that risk, so the FDA directs testing before treatment to guide monitoring, dosing, and counseling. A positive or homozygous result does not automatically rule out treatment. It reshapes the conversation: how closely you'll be watched with MRI, how the drug is titrated, and how you and your family weigh benefit against risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What APOE4 and ARIA actually mean
- Why testing happens before treatment
- What your specific result means for ARIA risk
- A high-risk result does not close the door
- Questions to bring to your appointment
- Frequently Asked Questions
What APOE4 and ARIA actually mean
APOE is a gene that comes in three common forms: ε2, ε3, and ε4. Everyone carries two copies, one from each parent. The ε4 version raises Alzheimer's risk—and, separately, raises the risk of ARIA during anti-amyloid therapy. you can carry zero, one (heterozygote), or two copies (homozygote).
ARIA stands for amyloid-related imaging abnormalities. According to the NIH genetics summary on ARIA, it appears on MRI as either brain swelling (ARIA-E, edema or effusion) or small bleeds and iron deposits (ARIA-H, microhemorrhage or siderosis). It is a class-wide effect of anti-amyloid antibodies. Most cases cause no symptoms, but a minority become serious.
Why testing happens before treatment
The FDA-approved prescribing information for lecanemab (leqembi) directs that ApoE ε4 testing be done before starting the drug, specifically to inform ARIA risk. The Leqembi FDA label allows treatment even without testing, but skipping the test means homozygote status—and its elevated risk—cannot be identified in advance. The same logic applies to donanemab (Kisunla).
Its label, available through DailyMed, likewise requires ApoE ε4 testing before starting and carries a boxed warning noting that ARIA risk is highest in ε4 homozygotes. Testing first lets your care team plan MRI monitoring and dosing around your genotype rather than reacting later. Both drugs are for early Alzheimer's. The FDA gave Leqembi full approval on July 6, 2023 for mild cognitive impairment or mild dementia with confirmed amyloid in the brain, per the FDA press announcement.
What your specific result means for ARIA risk
The numbers make the genotype matter. On the Leqembi label, ARIA occurred in 45% of ε4 homozygotes, 19% of heterozygotes, and 13% of noncarriers. Symptomatic ARIA-E—the version that actually causes symptoms—hit 9%, 2%, and 1% across those same groups.
Donanemab shows a similar pattern. Through 76 weeks of treatment, ARIA reached 55% in homozygotes, versus 36% in heterozygotes and 25% in noncarriers. Read as a scan-and-decide tool, your result sorts you into a risk band:.
- **No ε4 copies:** lowest ARIA risk, still monitored with MRI.
- **One ε4 copy:** moderate, roughly intermediate risk.
- **Two ε4 copies:** highest risk, and the strongest case for extra caution and counseling.
A high-risk result does not close the door
A homozygous result raises risk—it does not, by itself, forbid treatment. The Leqembi label frames ApoE testing as risk-stratification: it drives monitoring, dosing, and counseling, not automatic exclusion. Some homozygotes still choose treatment after weighing the tradeoffs with their doctor. Dosing strategy can also lower the risk.
In July 2025 the FDA approved an updated Kisunla titration—a slower, gradual dose ramp—shown to cut ARIA-E most in homozygotes. As reported by NeurologyLive, ARIA-E in that group fell from about 57% under standard dosing to about 19% with the modified titration. That is the practical payoff of testing before treatment. Knowing your genotype lets your team choose the titration schedule and MRI frequency that match your risk—before the first dose, not after a problem appears.
Questions to bring to your appointment
Use your result to steer a concrete conversation. A few worth raising: Symptoms of symptomatic ARIA can include headache, confusion, dizziness, vision changes, or nausea.
Report them promptly; even when ARIA is usually silent, the occasional serious case is why MRI monitoring exists. You can read the ApoE and ARIA sections directly in the Leqembi FDA prescribing information.
- How many ε4 copies do I carry, and what risk band does that put me in?
- How often will I get MRIs, and what symptoms should prompt an urgent call?
- Is a slower titration schedule appropriate for my genotype?
- If I'm a homozygote, do the expected benefits still justify the risk for me?
Frequently Asked Questions
Can I start Leqembi without APOE4 testing?
Yes. The FDA label permits treatment without testing, but then homozygote status and its elevated ARIA risk can't be identified beforehand.
Does two ε4 copies mean I can't be treated?
No. Homozygous status raises ARIA risk and calls for extra caution, but labels treat APOE testing as risk-stratification, not an exclusion rule.
Can anything reduce ARIA risk if I'm high-risk?
A slower titration schedule helped most. For donanemab, modified titration cut ARIA-E in homozygotes from about 57% to about 19%.
